A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Kylo-12 in Healthy Subjects
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Kylo 12 (Primary)
- Indications Hypertriglyceridaemia
- Focus Adverse reactions; First in man
- Sponsors Kylonova (Xiamen) Biopharma
- 29 Jan 2025 New trial record